X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA AUROBINDO PHARMA PLETHICO PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x -1.1 15.7 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PLETHICO PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
AUROBINDO PHARMA
Mar-17
PLETHICO PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs395895 44.1%   
Low Rs31622 5.0%   
Sales per share (Unadj.) Rs604.4254.6 237.4%  
Earnings per share (Unadj.) Rs32.539.3 82.7%  
Cash flow per share (Unadj.) Rs51.346.6 110.2%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs473.6160.0 296.0%  
Shares outstanding (eoy) m34.08585.88 5.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.43.0 11.8%   
Avg P/E ratio x6.619.3 34.0%  
P/CF ratio (eoy) x4.216.3 25.5%  
Price / Book Value ratio x0.54.7 9.5%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m7,262444,390 1.6%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m1,59617,678 9.0%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m20,598149,157 13.8%  
Other income Rs m3861,159 33.3%   
Total revenues Rs m20,984150,316 14.0%   
Gross profit Rs m2,81834,343 8.2%  
Depreciation Rs m6424,276 15.0%   
Interest Rs m1,593667 238.8%   
Profit before tax Rs m96930,558 3.2%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1387,597 -1.8%   
Profit after tax Rs m1,10723,012 4.8%  
Gross profit margin %13.723.0 59.4%  
Effective tax rate %-14.324.9 -57.5%   
Net profit margin %5.415.4 34.8%  
BALANCE SHEET DATA
Current assets Rs m18,87792,062 20.5%   
Current liabilities Rs m11,89666,223 18.0%   
Net working cap to sales %33.917.3 195.6%  
Current ratio x1.61.4 114.1%  
Inventory Days Days36106 33.9%  
Debtors Days Days19868 292.3%  
Net fixed assets Rs m9,86162,919 15.7%   
Share capital Rs m341586 58.1%   
"Free" reserves Rs m12,33193,133 13.2%   
Net worth Rs m16,13993,719 17.2%   
Long term debt Rs m4,7061,814 259.4%   
Total assets Rs m33,146162,494 20.4%  
Interest coverage x1.646.8 3.4%   
Debt to equity ratio x0.30 1,506.5%  
Sales to assets ratio x0.60.9 67.7%   
Return on assets %8.114.6 55.9%  
Return on equity %6.924.6 27.9%  
Return on capital %12.332.7 37.5%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40275,838 5.8%   
Fx outflow Rs m3,18430,224 10.5%   
Net fx Rs m1,21945,613 2.7%   
CASH FLOW
From Operations Rs m2,43732,786 7.4%  
From Investments Rs m-6,265-17,870 35.1%  
From Financial Activity Rs m2,490-19,153 -13.0%  
Net Cashflow Rs m-1,337-4,239 31.5%  

Share Holding

Indian Promoters % 82.7 54.1 152.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 8.0 54.1%  
FIIs % 5.5 27.7 19.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.2 73.5%  
Shareholders   10,665 69,601 15.3%  
Pledged promoter(s) holding % 85.7 8.6 1,001.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS